C2i Genomics deploys an innovative ctDNA MRD solution for personalized cancer detection and monitoring. C2i’s whole-genome technology provides ultra-high sensitivity with significantly reduced lab operation complexity, eliminate the need to develop a patient-specific assay, and allowing earlier detection of recurrent cancer, to inform better treatment decisions and improve outcomes.

Blueprint Medicines is a global precision therapy company that aims to invent life-changing medicines for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create therapies that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer and other genomically defined cancers, and cancer immunotherapy. (US-BP-MED-NP-22031)